I feel like swarms of ants are crawling all over my leg when I try to sleep. What's happening to me? DR MARTIN SCURR has the troubling answer
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
16 minutes ago
- Reuters
India's Apollo Hospitals to double AI investments, beats profit estimate
HYDERABAD, Aug 12 (Reuters) - India's Apollo Hospitals Enterprise ( opens new tab plans to double its investment in artificial intelligence capabilities over the next two to three years, its CEO said, after the company beat first-quarter profit estimates on higher patient volume. The hospital chain already uses AI tools in diagnosis to read X-rays, scan reports and also in endoscopy - a medical procedure to examine the inside of the body using a camera, CEO Madhu Sasidhar told Reuters on Tuesday. Many large private hospital chains in India, like their western counterparts, are investing in AI capabilities to improve patient diagnosis and decisions related to medical procedures, among others uses. Apollo recently developed technology to read existing scan reports and predict the risk of liver fibrosis in the future, Sasidhar said. "We are also bringing some other new generation agentic AI-type tools," he said. He did not quantify the size of Apollo's existing investment in AI. Apollo, headquartered in the south Indian city of Chennai, partnered with Microsoft (MSFT.O), opens new tab earlier this year to develop AI-based tools to be used in healthcare. Some of them are in early stages of testing, Sasidhar said. Indian hospital chains such as Apollo and Manipal have also been increasing their bed count for a larger share of the market, including through acquisitions of smaller hospital operators. Apollo said it is on track to add 4,370 beds over the next 3-4 years through acquisition, new hospitals and expansion of existing facilities. Its overall bed capacity is currently more than 10,000. The company's consolidated net profit rose 41.8% to 4.33 billion rupees ($49.40 million) for April-June, beating estimates of 3.86 billion rupees, according to data compiled by LSEG. While its overall occupancy rate dipped from last year, in-patient volume grew 3% and average revenue per in-patient increased by 9%, according to Apollo. Quarterly total revenue rose 15% to 58.42 billion rupees, beating estimates of 57.44 billion rupees. The company said it expects double-digit revenue growth for the current financial year. ($1 = 87.6520 Indian rupees)
Reuters
an hour ago
- Reuters
UK's PHP secures acceptance from 62.9% Assura shareholders, clears path for acquisition
Aug 12 (Reuters) - Primary Health Properties (PHP.L), opens new tab said on Tuesday it had secured acceptances for 62.9% of Assura (AGRP.L), opens new tab shares in its takeover bid for the British healthcare real estate investor. PHP confirmed that all remaining conditions to its revised $2.4 billion bid for Assura have now been satisfied, which implies that PHP can now proceed with the acquisition. Assura on Friday reiterated its support for PHP's takeover bid, despite rival suitor KKR (KKR.N), opens new tab urging it to back its competing offer. The U.S.-based private equity firm and PHP had been locked in a months-long battle for Assura before its board backed PHP's higher bid in June.
Reuters
an hour ago
- Reuters
US FDA approves Insmed's drug as first treatment for a chronic lung disease
Aug 12 (Reuters) - The U.S. Food and Drug Administration has approved Insmed's (INSM.O), opens new tab oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition. Shares of the New Jersey-based drugmaker rose 6% in morning trade. Insmed's drug, branded as Brinsupri, targets non-cystic fibrosis bronchiectasis, a chronic lung condition characterized by permanently damaged airways, leading to persistent cough and excessive mucus production. The condition affects 350,000 to 500,000 adults in the U.S., according to the American Lung Association. Brinsupri works by blocking certain inflammatory enzymes in white blood cells, preventing them from becoming overactive and damaging the lungs. Earlier treatments for the condition focused on controlling symptoms by using antibiotics, surgery or devices such as flutter valves to clear the airways. Insmed's application was based on a late-stage trial involving 1,680 adult and 41 adolescent patients, with the drug significantly reducing the frequency of respiratory symptoms such as chronic cough. The drug was found to be safe and well-tolerated at the two tested doses of 10 milligrams and 25 milligrams. TD Cowen analyst Ritu Baral expects the drug to reach peak sales of $3.7 billion in the United States by 2031. Brinsupri has the potential to drive future profitability for the company, she said. Rival treatments in development for the chronic lung condition include AstraZeneca's (AZN.L), opens new tab benralizumab and Zambon's inhaled antibiotic therapy CMS I-neb. This marks the second FDA approval for Insmed following Arikayce, which the agency cleared in 2018 to treat a chronic lung infection caused by bacteria commonly found in soil and water.
